RxSight, Inc.
NASDAQ:RXSTMedical - Devices
+$0.05 today
- Market cap
- $210.07M
- Beta
- 1.13
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$1.13
Volume 0.74M
Average 0.80M
RXST Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
RxSight, Inc.NASDAQ: RXST
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 37.2% from a year ago
Cash & equivalents stood at $17.57M at the end of Q1 FY2026, down 37.2% from a year earlier and down 11.9% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.
Context
- Cash & equivalents amounted to 5.8% of total assets at the end of Q1 FY2026, down 3.2 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -37.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 19.95M USD
- Year-over-year change
- +19.4%
- 4-year CAGR
- -4.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.95M | +19.4% |
| FY2024 | 2024-12-31 | 16.71M | +72.4% |
| FY2023 | 2023-12-31 | 9.69M | -18.1% |
| FY2022 | 2022-12-31 | 11.83M | -51.4% |
| FY2021 | 2021-12-31 | 24.36M | — |
Cash & Equivalents vs competitors
How RXST compares with its peers on the latest reported figures
- RXST's Mar 2026 cash & equivalents of $17.57M is the 5th highest of the 9 companies compared; the peer median is $21.31M.
- Its year-over-year change of -37.2% is the 7th highest of 9, against a peer median of -10.7%.
- Cash & equivalents amounts to 5.8% of total assets for RXST, versus a peer median of 13.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $137.95M | -11.1% | -2.5% | 48.2% | |
| Mar 2026 | $74.99M | -10.3% | +56.1% | 27.6% | |
| Mar 2026 | $41.31M | +223.4% | +78.3% | 33.1% | |
| Mar 2026 | $27.85M | +43.0% | -17.5% | 12.5% | |
| Mar 2026 | $17.57M | -37.2% | +19.0% | 5.8% | |
| Mar 2026 | $14.78M | -45.3% | +48.6% | 14.9% | |
| Mar 2026 | $14.25M | -57.4% | +29.6% | 2.8% | |
| Mar 2026 | $9.54M | -28.6% | -18.1% | 5.2% | |
| Mar 2026 | $4.87M | +88.0% | +49.0% | 9.2% | |
| Peer median (excluding RXST) | $21.31M | -10.7% | +39.1% | 13.7% | |
Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 24.36M | 11.83M | 9.69M | 16.71M | 19.95M |
| Short-term Investments | 134.97M | 93.97M | 117.49M | 220.52M | 208.18M |
| Net Receivables | 4.86M | 10.96M | 20.28M | 30.05M | 23.38M |
| Inventory | 8.03M | 14.84M | 17.42M | 22.01M | 31.56M |
| Other Current Assets | 0 | 2.96M | 3.52M | 4.54M | 4.39M |
| Total Current Assets | 176.3M | 134.56M | 168.41M | 293.82M | 287.46M |
| Property, Plant & Equipment (Net) | 15.5M | 14.08M | 13.29M | 23.63M | 23.02M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 711K | 750K | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 925K | 1.53M | 147K | 360K | 1.34M |
| Total Non-current Assets | 16.43M | 15.61M | 14.14M | 24.74M | 24.36M |
| Total Assets | 192.72M | 150.16M | 182.55M | 318.56M | 311.81M |
| Account Payables | 1.69M | 2.6M | 3.86M | 4.54M | 5.3M |
| Short-term Debt | 0 | 0 | 0 | 974K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 618K | 1.35M | 2.05M | 3.11M | 3.6M |
| Other Current Liabilities | 6.92M | 10.87M | 2.56M | 2.79M | 16.2M |
| Total Current Liabilities | 11.08M | 17.24M | 20.9M | 25.88M | 26.25M |
| Long-term Debt | 39.76M | 40.17M | 0 | 0 | 9.88M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 74K | 127K | 0 |
| Total Non-current Liabilities | 43.4M | 43.03M | 1.29M | 11.45M | 9.88M |
| Total Liabilities | 54.48M | 60.26M | 22.19M | 37.33M | 36.13M |
| Common Stock | 27K | 28K | 36K | 40K | 41K |
| Retained Earnings | (479.28M) | (546.03M) | (594.64M) | (622.1M) | (661.04M) |
| Accumulated OCI | (20K) | (95K) | (5K) | 166K | 53K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 138.24M | 89.9M | 160.36M | 281.24M | 275.68M |
| Total Debt | 44.93M | 45M | 3.01M | 12.3M | 11.04M |
| Net Debt | 20.57M | 33.16M | (6.68M) | (4.41M) | (8.91M) |
RxSight, Inc.
NASDAQ:RXST
Intrinsic Alpha fair value
Locked
Current Price
$5.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.